FN1 and cancer: Compound ITP-79 inhibited the binding of TG2 peptide to the 42-KDA FN fragment in a dose-dependent manner, thereby disrupting FN - α5β1 integrin complexes and blocking the adhesion of cancer cells to mesothelial cells (64).